Dr. Xin Yao, MD

Dr. Yao practices at Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida.

Dr. Yao's NPI, 1174670145, was assigned on January 4, 2007. Dr. Yao holds Florida license MEL152838.

Dr. Yao's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West, at 1708 Cape Coral W Pkwy, Cape Coral, FL 33914 in Lee County. The practice phone is (239) 541-4633.

Dr. Yao's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida. Dr. Yao is also affiliated with Lee Memorial Hospital. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Yao to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yao practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Yao's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Yao is board certified in hematology by the American Board of Internal Medicine. Dr. Yao is licensed in Florida.

CMS data shows 1,036 Medicare services from Dr. Yao across 10 procedure codes in 2024, for 296 Medicare patients. Medicare paid $81,992 for them.

CMS counts 296 Medicare patients who saw Dr. Yao in 2024. The largest group is 75 to 84, with 118 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yao's median patient age at 71, with 50% women.

In 2024, Dr. Yao wrote 459 Medicare Part D claims for 118 patients. 61% of them were for generic drugs. CMS names the drug for 250 of them, across 12 drugs with 11 or more claims each, at $758,604 in total drug cost. In 2023, CMS named 93 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Yao for performance year 2024, reported through an alternative payment model (APM). Dr. Yao accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Yao as offering telehealth.

Dmand AI links 122 papers to Dr. Yao, published from 2011 to 2025. 2024 was the busiest year, with 21. The most frequent topics are Solubility, Polymers and Plant Proteins. Dr. Yao has published most often in Mol Pharm. Dr. Yao's most frequent co-authors are John A. Charlson, MD, Yee Chung C. Cheng, MD and Christopher R. Chitambar, MD.

Dmand AI links Dr. Yao to 8 clinical trials, 3 of them phase 2/3 studies. 7 are still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Adenocarcinoma Of Esophagus. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 84 general payments to Dr. Yao from 30 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 80% of the total. AstraZeneca Pharmaceuticals LP paid the most, $624.